Intraarterial Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb Ischemia

Abstract

Intraarterial administration of BM-MNC is safe and feasible and accelerates wound healing in patients without extensive gangrene and impending amputation. These exploratory findings of this pilot trial need to be confirmed in a larger randomized trial in patients with critical limb ischemia and stable ulcers.